{"commentary":{"count":23,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":11,"youtube":10,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06072781\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"RAMP 301","nct_id":"NCT06072781","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ramp-301-nct06072781. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"RAMP 301","arms":[{"description":"Avutometinib 3.2 mg, PO, twice weekly for 21 days on, 7 days off in a 28-day (4 weeks) cycle in combination with defactinib 200 mg, PO, twice daily for 21 days on, 7 days off in a 28-day(4 week) cycle.","label":"avutometinib + defactinib","type":"EXPERIMENTAL"},{"description":"Patients will receive one of the following therapies as determined by the Investigator:\n\n* Pegylated liposomal doxorubicin: 40 mg/m2 IV on Day 1 of each 28-day (4 week) cycle.\n* Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15 of each 28-day (4 week) cycle.\n* Anastrozole: 1 mg, PO, once daily of each 28-day (4 week) cycle.\n* Letrozole: 2.5 mg, PO, once daily of each 28-day (4 week) cycle.","label":"Investigator Choice of Treatment (ICT)","type":"ACTIVE_COMPARATOR"}],"collaborators":["GOG Foundation","European Network of Gynaecological Oncological Trial Groups (ENGOT)","Australia New Zealand Gynaecological Oncology Group","Korean Gynecologic Oncology Group"],"completion_date":{"date":"2031-02-09","type":"ESTIMATED"},"conditions":["Low Grade Serous Ovarian Cancer"],"enrollment":{"count":270,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"avutometinib","type":"DRUG"},{"name":"Defactinib","type":"DRUG"},{"name":"Pegylated liposomal doxorubicin","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Letrozole","type":"DRUG"},{"name":"Anastrozole","type":"DRUG"}],"last_update":"2026-10-07","lead_sponsor":"Verastem, Inc.","official_title":"A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-10-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) per blinded independent central review (BICR)","timeFrame":"Up to 24 months"}],"references":[{"citation":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201. Future Oncol. 2025 Dec;21(30):3859-3871. doi: 10.1080/14796694.2025.2595130. Epub 2025 Dec 12.","pmid":"41384753","type":"DERIVED"},{"citation":"Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, Prendergast E, Oaknin A, Ring K, Colombo N, Holloway RW, Rodrigues M, Chon HS, Gourley C, Santin AD, Thaker PH, Gennigens C, Newman G, Salinas E, Youssoufian H, Moore KN, Lustgarten S, O'Malley DM, Van Gorp T, Grisham RN. Efficacy and Safety of Avutometinib +/- Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. J Clin Oncol. 2025 Sep;43(25):2782-2792. doi: 10.1200/JCO-25-00112. Epub 2025 Jul 11.","pmid":"40644648","type":"DERIVED"},{"citation":"Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer. Int J Gynecol Cancer. 2025 Nov;35(11):101832. doi: 10.1136/ijgc-2024-005919. Epub 2025 Apr 19.","pmid":"39375168","type":"DERIVED"}],"start_date":{"date":"2024-03-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer","url":"https://clinicaltrials.gov/study/NCT06072781"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ramp-301-nct06072781"}